Antisense compounds, compositions and methods are provided for modulating the expression of SRC-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-2. Methods of using these compounds for modulation of SRC-2 expression and for treatment of diseases associated with expression of SRC-2 are provided.
Claims What is claimed is: 1. An antisense compound 15 to 30 nucleobases in length targeted to nucleotides 71 through 88 of a 5' untranslated region, nucleotides 157 through 181 of a start codon region, nucleotides 225 through 242, nucleotides 358 through 375, nucleotides 438 through 455, nucleotides 495 through 512, nucleotides 548 through 565, nucleotides 595 through 612, nucleotides 642 through 659, nucleotides 692 through 709, nucleotides 778 through 795, nucleotides 845 through 862, nucleotides 936 through 953, nucleotides 1075 through 1092, nucleotides 1265 through 1282, nucleotides 1475 through 1492, nucleotides 1667 through 1684, nucleotides 1805 through 1822, nucleotides 2060 through 2077, nucleotides 2162 through 2179, nucleotides 2371 through 2388, nucleotides 2492 through 2509, nucleotides 2613 through 2630, nucleotides 2748 through 2765, nucleotides 2944 through 2961, nucleotides 3063 through 3080, nucleotides 3342 through 3354, nucleotides 3552 through 3569, nucleotides 3746 through 3763, nucleotides 3872 through 3889, nucleotides 4012 through 4029, nucleotides 4182 through 4199, or nucleotides 4407 through 4424 of a coding region, nucleotides 4539 through 4566 of a stop codon region, or nucleotides 4695 though 4712 or nucleotides 4828 through 4845 of a 3'-untranslated region of a nucleic acid molecule encoding human SRC-2 (SEQ ID NO:3), wherein said antisense compound specifically hybridizes with one of said regions and inhibits the expression of human SRC-2. 2. The antisense compound of claim 1 which is an antisense oligonucleotide. 3. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The antisense compound of claim 3, wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The antisense compound of claim 5, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The antisense compound of claim 7, wherein the modified nucleobase is a 5-methylcytosine. 9. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the antisense compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of SRC-2 in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of SRC-2 is inhibited. 14. An antisense compound up to 30 nucleobases in length consisting of SEQ ID NO: 1, 15, 16, 17, 23, 25, 27, 29, 30, 31, 32, 38, 39, 40, 41, 42, 47, 48, 12, 13, 18, 20, 22, 36, 37, 43, 44, 45 or 46 which inhibits the expression of human SRC-2. 15. The antisense compound of claim 14 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The antisense compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 24. The composition of claim 23, further comprising a colloidal dispersion system. 25. The composition of claim 23, wherein the antisense compound is an antisense oligonucleotide. 26. A method of inhibiting the expression of human SRC-2 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 14, so that expression of human SRC-2 is inhibited. 